5 active not recruiting. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Active not recruiting 5 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia Zanubrutinib - Waldenström's Macroglobulinemia | Phase 4 | Active not recruiting | BeiGene | 16 | 2025-10-17 | 2026-08-10 |
| A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma Teclistamab - Multiple Myeloma | Phase 4 | Active not recruiting | Johnson & Johnson Private Limited | 75 | 2025-05-22 | 2026-09-25 |
| Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers 0.9% Sodium Chloride Injection, Lidocaine Injection 2% - Ehlers-Danlos Syndrome, Anesthesia, Local | Phase 4 | Active not recruiting | University of Calgary | 155 | 2022-11-10 | 2024-12-18 |
| STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA Velcade, Melphalan, Prednisone - Multiple Myeloma | Phase 4 | Active not recruiting | University of Turin, Italy | 450 | 2019-01-03 | 2025-12-03 |
| Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) 2-dose PCV13, 1-dose PCV13 - Multiple Myeloma | Phase 4 | Active not recruiting | National Taiwan University Hospital | 101 | 2016-03-23 | 2025-09-04 |
Multiple Myeloma (3) · Ehlers-Danlos Syndrome (1) · Waldenstrom Macroglobulinemia (1)
Cardiovascular Diseases (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Hemorrhagic Disorders (5) · Vascular Diseases (5) · Blood Protein Disorders (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Plasma Cell (4) · Paraproteinemias (4) · Collagen Diseases (1)
Bortezomib (1) · Dexamethasone (1) · Lenalidomide (1) · Lidocaine (1) · Melphalan (1) · Prednisone (1) · Sodium Chloride (1) · daratumumab (1) · zanubrutinib (1)
BeiGene (1) · Johnson & Johnson Private Limited (1) · National Taiwan University Hospital (1) · University of Calgary (1) · University of Turin, Italy (1)
Canada (1) · China (1) · India (1) · Italy (1) · Taiwan (1)
Hsin-Yun Sun, M.D., Ph.D. (1) · Satish R Raj, MD MSCI (1)